SV2003001107A - Imidazotriazinas ref.lea 35368 - Google Patents

Imidazotriazinas ref.lea 35368

Info

Publication number
SV2003001107A
SV2003001107A SV2002001107A SV2002001107A SV2003001107A SV 2003001107 A SV2003001107 A SV 2003001107A SV 2002001107 A SV2002001107 A SV 2002001107A SV 2002001107 A SV2002001107 A SV 2002001107A SV 2003001107 A SV2003001107 A SV 2003001107A
Authority
SV
El Salvador
Prior art keywords
imidazotriazinas
lea
ref
preparation
imidazotriazines
Prior art date
Application number
SV2002001107A
Other languages
English (en)
Inventor
Marcus Bauser
Dietmar Flubacher
Irene Gerlach
Volker Hinz
Reinhard Jork
Paul Naab
Ulrich Niewohner
Juergen Stoltefuss
Martin Hendrix
Jens-Kerim Erguden
Nils Burkhardt
Arno Friedel
Thorsten-Oliver Repp
Karl-Heinz Schlemmer
David Bruckner
Dagmar Schauss
Adrian Tersteegen
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV2003001107A publication Critical patent/SV2003001107A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVAS IMIDAZOTRIAZINAS, A PROCEDIMIENTOS PARA SU PREPARACION Y A SU USO PARA LA PREPARACION DE MEDICAMENTOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DE ENFERMEDADES NEURODEGENERATIVAS, ESPECIALMENTE DE LA ENFERMEDAD DE PARKINSON.
SV2002001107A 2001-06-22 2002-06-21 Imidazotriazinas ref.lea 35368 SV2003001107A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10130167A DE10130167A1 (de) 2001-06-22 2001-06-22 Imidazotriazine

Publications (1)

Publication Number Publication Date
SV2003001107A true SV2003001107A (es) 2003-03-18

Family

ID=7689090

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002001107A SV2003001107A (es) 2001-06-22 2002-06-21 Imidazotriazinas ref.lea 35368

Country Status (11)

Country Link
US (1) US6936609B2 (es)
EP (1) EP1404677A1 (es)
JP (1) JP2004534827A (es)
AR (1) AR036103A1 (es)
CA (1) CA2451525A1 (es)
DE (1) DE10130167A1 (es)
DO (1) DOP2002000429A (es)
GT (1) GT200200122A (es)
PE (1) PE20030129A1 (es)
SV (1) SV2003001107A (es)
WO (1) WO2003000693A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2689444T3 (es) * 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
AU2008230710B2 (en) * 2007-03-27 2014-04-10 Omeros Corporation The use of PDE7 inhibitors for the treatment of movement disorders
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
DE102007060172A1 (de) 2007-12-13 2009-06-25 Bayer Healthcare Ag Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102008035209A1 (de) 2008-07-29 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
AU2009287621B2 (en) * 2008-09-04 2012-09-20 Mitsubishi Tanabe Pharma Corporation Tri-substituted pyrimidine compounds and their use as PDE10 inhibitors
US20110166135A1 (en) * 2008-09-10 2011-07-07 Hiroshi Morimoto Aromatic nitrogen-containing 6-membered ring compounds and their use
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
ES2540867T3 (es) 2010-02-26 2015-07-14 Mitsubishi Tanabe Pharma Corporation Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
KR20130083389A (ko) * 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US8772316B2 (en) 2011-02-18 2014-07-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
EP2681218A1 (en) * 2011-02-23 2014-01-08 Pfizer Inc IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
JP2014231475A (ja) * 2011-08-25 2014-12-11 田辺三菱製薬株式会社 新規化合物及びそのｐｄｅ１０阻害薬としての使用
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
AU2014221799B2 (en) 2013-02-27 2017-09-28 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
CA2910759C (en) 2013-05-02 2018-01-16 Pfizer Inc. Imidazo-triazine derivatives as pde10 inhibitors
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
WO2024038089A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
SK287161B6 (sk) * 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
WO2001024781A2 (en) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulating same

Also Published As

Publication number Publication date
JP2004534827A (ja) 2004-11-18
GT200200122A (es) 2003-06-05
PE20030129A1 (es) 2003-03-13
US20040249148A1 (en) 2004-12-09
DE10130167A1 (de) 2003-01-02
EP1404677A1 (de) 2004-04-07
WO2003000693A1 (de) 2003-01-03
DOP2002000429A (es) 2003-10-15
AR036103A1 (es) 2004-08-11
US6936609B2 (en) 2005-08-30
CA2451525A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
SV2003001107A (es) Imidazotriazinas ref.lea 35368
BR0213358A (pt) Uso de flibanserina
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
BRPI0409611A (pt) derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
PA8543301A1 (es) Derivados de dihidro-benzo (b) (1,4) diazepin-2 -ona como antagonistas ii mglur2
WO2003080582A3 (de) Fredericamycin-derivate
BRPI0410029A (pt) dihidroquinazolinas substituìdas
UY27392A1 (es) Derivados del ácido indan acetico y su uso como agentes farmacéuticos, intermediarios, y método de preparación
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
SV2006002290A (es) Nonadepsipeptidos acilados ii ref. bhc041327-sv
DK1778623T3 (da) Derivater af 1-phenylalkancarboxylsyrer til behandling af neurodegenerative sygdomme
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
SV2003001061A (es) Nuevos heterociclos 3 ref.lea 35361-sv
SV2002000355A (es) Aril- y heteroarilsulfonatos ref. lea 34321-sv
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
SV2002000639A (es) Alcanosulfonatos de fenoxifenilo ref. lea 34813-sv

Legal Events

Date Code Title Description
FD Lapse